Companies › Vor Biopharma
1 active drug program in 2 registered trials: 2 Phase 3; Neurology, Immunology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Telitacicept | – | Phase 3 | Generalized Myasthenia Gravis; Primary Sjogren's Disease | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06456580 | Telitacicept | Phase 3 | Generalized Myasthenia Gravis | Neurology | Mar 2027 |
| NCT07404865 | Telitacicept | Phase 3 | Primary Sjogren's Disease | Immunology | Dec 2028 |
Cash and short-term investments of $482m on 2026-09-30; operating cash outflow about $129m a year; runway about 45 months at that burn, to Jun 2030; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Zenas BioPharma (USA) Chengdu Kangnuoxing Biopharma Dianthus Therapeutics Q32 Bio Keros Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.